News & Media

Events
Interim Report January - September 2020

Read more
Events
Interim Report January - June 2020

Read more
Events
Interim Report January - March 2020

Read more
Events
Annual General Meeting 2020

The Annual General Meeting 2020 will be held on 5 May at 2pm CET, at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm.

Read more
Press release
Medivir 2019 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2019 now is available at the...

Read more
Press release
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB are hereby summoned to the annual general meeting on Tuesday 5 May 2020 at 2 p.m....

Read more
Press release
Medivir and Tango Therapeutics sign license agreement for preclinical asset

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered into a license agreement with US biotech...

Read more
Press release
First liver cancer patient dosed in the MIV-818 phase Ib study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with advanced liver cancer has been dosed...

Read more
Press release
Medivir presents positive data from the completed phase Ia study with MIV-818 in patients with advanced liver cancer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that new data from the completed phase Ia study with MIV-818 will...

Read more
Press release
Invitation to Medivir's R&D Day on March 2, 2020

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to a R&D Day in Stockholm, Monday...

Read more
Press release
Medivir and Shijiazhuang Yuanmai Biotechnology sign licensing agreement regarding manufacturing and sales of Xerclear® in China

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the company has signed a licensing agreement for Medivir's Xerclear® for...

Read more
Press release
MEDIVIR AB – YEAR END REPORT JANUARY – DECEMBER 2019

Continued progress with our proprietary and wholly owned candidate drug MIV-818 for liver cancer October – December Significant events during the...

Read more